Clinical trial · Observational
Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy
Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy: A Retrospective Cohort Study
NCT05489458CI-TRIAL-00060139PF-BARNAunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Radical surgical resection is the only curative treatment option for pancreatic cancer, but borderline resectable tumors have a high probability of incomplete exeresis. Although neoadjuvant therapy can improve the chances of complete exeresis, not all patients respond as expected.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Pancreatic Ductal | Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No Resection | Procedure | — | UNRESOLVED |
| Resection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Exploratory Surgery with Resection
- description
- Type A BR-PDAC patients that underwent surgical exploration after neoadjuvant therapy and had their tumors resected.
- interventionNames
- Procedure: Resection
- label
- Exploratory Surgery without Resection
- description
- Type A BR-PDAC patients that underwent surgical exploration after neoadjuvant therapy and did not have their tumors resected.
- interventionNames
- Procedure: No Resection
Primary outcomes (9)
- measure
- The number of type A BR-PDAC patients who, after receiving NAT (≥3 cycles), undergo resection.
- timeFrame
- From 6 weeks until the end of the observation period (December 2019) or death (whichever occurs first)
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients ≥18 years old. * Both sexes. * Diagnosed with a type A BR-PDAC between January 2010 and December 2019. * Minimum follow-up period of 12 months. Exclusion Criteria: * Patients diagnosed with a type B or type C BR-PDAC. * Patients diagnosed with a type A BR-PDAC who had disease progression prior to receiving NAT.
References
Publications (0)
Data not yet available
No reference posted for this study.